Last updated: June 28, 2026
ecutive summary
No complete, reliable supplier map can be produced for “LO-MALMOREDE” because the drug identity, active ingredient, dosage form, and reference product are not specified, and “LO-MALMOREDE” does not uniquely resolve to a single, mappable FDA/Orange Book or global trade-name record from which manufacturer and API/formulation suppliers can be enumerated.
What suppliers make LO-MALMOREDE pharmaceutical products and APIs?
Featured snippet answer: Not identifiable from the provided name alone.
How to map “LO-MALMOREDE” to an API and reference product
A supplier list requires a determinable target:
- Drug substance (INN/USAN active ingredient)
- Finished dosage form (tablet, capsule, oral solution, injection, etc.)
- Strengths and labeling (US labeler, NDA/BLA, or marketing authorization holder)
- Country-specific product code or submission identifier
Without that linkage, supplier identification would be guesswork, not patent- or regulatory-grade intelligence.
Which companies supply LO-MALMOREDE to pharmacies, hospitals, and distributors?
Featured snippet answer: Not determinable from the provided identifier.
What “supplier” means in regulatory terms
High-integrity supplier mapping usually pulls from one or more of:
- FDA labeling “Labeler” (NDC)
- Orange Book “Listed Drug” and manufacturing sites
- Drug Master File (DMF) holders for excipients or process aids
- API suppliers tied to DMFs and ANDA/505(b)(2) dossiers
- Wholesale distributor listings by NDC and labeler
“LO-MALMOREDE” must first be resolved to an NDC/labeler or marketing authorization holder.
What is the Orange Book status of LO-MALMOREDE (NDA, ANDA, exclusivity)?
Featured snippet answer: Cannot be determined from the provided name.
What is required for Orange Book lookup-grade results
- Correct proprietary name and active ingredient
- NDA/BLA number or at minimum the exact FDA-listed proprietary name spelling
- Dosage form and strength
Which manufacturers make LO-MALMOREDE finished dosage forms (tablet, capsule, liquid, injection)?
Featured snippet answer: Not determinable from the provided identifier.
Common manufacturing intelligence sources (only after product resolution)
- FDA Establishment Registration and Drug Listing (DERP)
- Site-level manufacturing data from NDA/ANDA chemistry and controls sections
- GMP inspection records tied to the labeler’s manufacturing sites
Do any patent estates or Paragraph IV challenges affect LO-MALMOREDE supply?
Featured snippet answer: Cannot be evaluated without an active ingredient and reference product.
Why supplier mapping depends on product identity
Patent status drives:
- Which ANDAs can launch
- Which manufacturers are contractually tied to a platform or settlement
- Whether supply depends on authorized generics, exclusivity blockers, or licensing
Key Takeaways
- A supplier and manufacturer list for “LO-MALMOREDE” cannot be produced without resolving the name to a unique active ingredient, dosage form, and regulatory reference product.
- Any attempt to list companies, APIs, or manufacturing sites from this identifier alone would not meet high-stakes patent and regulatory analysis standards.
FAQs
- What does LO-MALMOREDE correspond to (active ingredient and reference product)?
- How do I find the FDA NDC labeler for a drug name if the spelling varies?
- Where can finished dosage manufacturers be verified besides the label?
- How are API suppliers identified when the drug is marketed under a different proprietary name?
- What data sources best connect ANDA filings to API and formulation manufacturers?
References
No sources cited because the drug identity required for citation-grade supplier mapping is not provided.
